-
Hydrochlorothiazide
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Hydrochlorothiazide 58-93-5 16750 Commercial Production [Indication]
1. For the treatment of edematous conditions, such as those associated with congestive heart failure, cirrhosis of the liver, and nephrotic syndrome.
2. In the management of essential (primary) hypertension, either as monotherapy or in combination with other antihypertensive agents.
3. For the treatment of diabetes insipidus of central or nephrogenic origin.
4. For the prevention of calcium-containing renal calculi (kidney stones).